CRO Medpace Eyes $1 Billion IPO

Published: Apr 25, 2016

Pharmaceutical services company Medpace Inc is preparing for a potential initial public offering in the United States that could value the pharmaceutical contract research organization at more than $1 billion, including debt, according to people familiar with the matter.

Medpace, which is owned by private equity firm Cinven Ltd, has already filed a confidential IPO registration statement with the U.S. Securities and Exchange Commision (SEC), the people said this week.

Under U.S. President Barack Obama's Jobs Act, which was signed into law in 2012, so-called "emerging growth" companies with less than $1 billion in annual revenue can file for an IPO with the SEC confidentially, allowing them to resolve any regulatory issues out of the public eye.

Back to news